Accuray Receives 510(K) Clearance From The U.S. Food And Drug Administration For Its VitalHold Breast Package On The Radixact System
Portfolio Pulse from Benzinga Newsdesk
Accuray Incorporated (ARAY) has received 510(K) clearance from the U.S. Food and Drug Administration for its VitalHold Breast Package on the Radixact System. This approval could potentially increase the company's market share in the medical devices sector.
August 10, 2023 | 6:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Accuray's FDA clearance for its VitalHold Breast Package on the Radixact System could potentially increase its market share in the medical devices sector.
The FDA clearance is a significant regulatory milestone for Accuray, allowing it to market and sell its VitalHold Breast Package on the Radixact System in the U.S. This could potentially increase the company's market share in the medical devices sector, which would likely have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100